Cue Biopharma Inc [NASDAQ: CUE] gained 18.27% or 0.11 points to close at $0.76 with a heavy trading volume of 5676997 shares.
The daily chart for CUE points out that the company has recorded -72.73% loss over the past six months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
If we look at the average trading volume of 399.49K shares, CUE reached to a volume of 5676997 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Cue Biopharma Inc [CUE]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CUE shares is $5.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CUE stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Jefferies have made an estimate for Cue Biopharma Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on March 13, 2024. While these analysts kept the previous recommendation, Oppenheimer raised their target price to Outperform. The new note on the price target was released on June 26, 2023, representing the official price target for Cue Biopharma Inc stock. Previously, the target price had yet another raise to $7, while Piper Sandler analysts kept a Overweight rating on CUE stock.
The Average True Range (ATR) for Cue Biopharma Inc is set at 0.11, with the Price to Sales ratio for CUE stock in the period of the last 12 months amounting to 5.30. The Price to Book ratio for the last quarter was 1.24, with the Price to Cash per share for the same quarter was set at 0.84.
Trading performance analysis for CUE stock
Cue Biopharma Inc [CUE] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 3.03. With this latest performance, CUE shares dropped by -38.31% in over the last four-week period, additionally sinking by -72.73% over the last 6 months – not to mention a drop of -80.08% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CUE stock in for the last two-week period is set at 35.41, with the RSI for the last a single of trading hit 39.97, and the three-weeks RSI is set at 35.09 for Cue Biopharma Inc [CUE]. The present Moving Average for the last 50 days of trading for this stock 1.2554, while it was recorded at 0.6962 for the last single week of trading, and 1.9924 for the last 200 days.
Cue Biopharma Inc [CUE]: A deeper dive into fundamental analysis
Cue Biopharma Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.47 and a Current Ratio set at 2.47.
An analysis of Institutional ownership at Cue Biopharma Inc [CUE]
The top three institutional holders of CUE stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.5034%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $178.43 billion in CUE stocks shares; and BERKSHIRE HATHAWAY INC, currently with $135.36 billion in CUE stock with ownership which is approximately 5.1238%.
